Product information and disease descriptionProduct descriptionProduct information
Dosage forms and strengths
4 evidence topics · 5 sources
Subcutaneous formulation: vial and syringe, then autoinjector, in phase 3
Subcutaneous formulation: phase 3 dose strengths
Oral formulation: once-daily tablet and phase 3 dose strengths
Subcutaneous and oral formulations: contracted finished-product formats
Commercial strengths, package configuration, and national drug code
No evidence found.